EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Madecassoside Part I: From Biosynthesis to Druggability

Yuping Li, Mengdan Xu, Yuting Yang, Shanshan Liang, Yucui Lu, Xianmei Lin, Lichun Zhao

Biomolecules · 2026-11-14 · 16 (11) · 1663

DOI: 10.3390/biom16111663 ↗

At a glance

Journal article in Biomolecules, published online on 2026-11-14. Written by Yuping Li and 6 co-authors. The full text is freely available (open access, CC BY 4.0). Funded by: Guizhou University of Traditional Chinese Medicine, Guizhou Provincial Science and Technology Innovation Leading Talents Workstation for Elemental Chinese Materia Medica Innovation and High-Efficiency Utilization, Guizhou Provincial Basic Research Program.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Madecassoside (MA) is the core bioactive pentacyclic triterpenoid saponin and a key quality control marker of Centella asiatica (L.) Urb. Its material basis and druggability profiles are fundamental prerequisites for pharmacological research and clinical translation. Although several reviews have covered selected aspects of MA chemistry and pharmacology, no systematic review has comprehensively covered the full chain from chemical structure to in vivo disposition exclusively for MA monomer.

Objective

As the first part of a two-part series, this review aims to systematically integrate evidence on the chemical basis, biosynthesis, green preparation, and pharmacokinetic characteristics of MA and clarify the core druggability bottlenecks of this compound.

Methods

The literature search was conducted in PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) up to 31 August 2026. Studies focusing on the chemistry, biosynthesis, extraction/purification, and pharmacokinetics of MA were included and critically analyzed. Evidence was stratified into four predefined levels: Level A (clinical trials), Level B (in vivo animal studies), Level C (in vitro cell/molecular studies), Level D (computational prediction). The limitation of Chinese literature to Peking University core journals is acknowledged as a potential source of publication bias.

Results

Current evidence supports that the C-6 β-hydroxyl group on the ursane-type aglycone skeleton and the intact linear trisaccharide chain at the C-28 position are the major structural correlates of MA’s biological activity (working hypothesis based on natural analog comparisons). The backbone cyclization and glycosylation steps in the MA biosynthetic pathway have been largely characterized, but the specific enzymes responsible for C-2 α- and C-6 β-hydroxylation remain to be fully identified. Green extraction technologies such as ultrasound-assisted extraction, microwave-assisted extraction, and deep eutectic solvent extraction have been well optimized, and multiple purification strategies can yield high-purity monomers. In rats, the oral absolute bioavailability of the pure MA prototype is less than 1%, with extensive intestinal metabolism and enterohepatic circulation, representing the core druggability bottleneck. Human pharmacokinetic data remain very limited, and rat values cannot be directly extrapolated to humans.

Conclusions

This review establishes a full-chain material basis framework for madecassoside spanning from molecular structure to in vivo disposition, systematically integrating evidence on structural activity determinants, biosynthetic pathways, green extraction and purification technologies, and pharmacokinetic profiles. Extremely low oral bioavailability and extensive in vivo metabolic transformation are confirmed as the core druggability bottlenecks. These findings lay the essential foundation for elucidating pharmacological mechanisms, optimizing delivery systems, and advancing clinical translation in the second part of this series. To our knowledge, this is the first two-part systematic review focused exclusively on the MA monomer that covers the full translational spectrum from chemical fundamentals and druggability profiles to pharmacological mechanisms and clinical translation.

Funding

  • Guizhou University of Traditional Chinese Medicine
  • Guizhou Provincial Science and Technology Innovation Leading Talents Workstation for Elemental Chinese Materia Medica Innovation and High-Efficiency Utilization
  • Guizhou Provincial Basic Research Program
  • Guizhou University of Traditional Chinese Medicine Postgraduate Education Innovation Program Project
  • Guizhou Provincial Administration of Traditional Chinese Medicine Project

Cite

APA

Li, Y., Xu, M., Yang, Y., Liang, S., Lu, Y., Lin, X., & Zhao, L. (2026). Madecassoside Part I: From Biosynthesis to Druggability. Biomolecules, 16(11), 1663. https://doi.org/10.3390/biom16111663

Vancouver

Li Y, Xu M, Yang Y, Liang S, Lu Y, Lin X, et al. Madecassoside Part I: From Biosynthesis to Druggability. Biomolecules. 2026;16(11):1663. doi:10.3390/biom16111663

BibTeX
@article{Li2026,
  author = {Li, Yuping and Xu, Mengdan and Yang, Yuting and Liang, Shanshan and Lu, Yucui and Lin, Xianmei and Zhao, Lichun},
  title = {Madecassoside Part I: From Biosynthesis to Druggability},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {1663},
  doi = {10.3390/biom16111663}
}
Start for free →